Twitter

Chordate Medical expands international exposure at INS 2022 in Barcelona

After a long pandemic break, scientific congresses are now resumed globally in Life science. For Chordate Medical, INS 2022 is the first in a series of congresses where the company demonstrates its technology K.O.S. INS stands for International Neuromodulation Society and is focused on innovation and investments in neuromodulation.

Jan Hermansson, CSO Chordate Medical, in discussion with a research nurse from Finland.

“This is one of our most important platforms to be exposed to, both to meet doctors who are at the forefront of clinical development, and as exposure to industrial and financial actors. The interest in new treatment methods for chronic migraine that are not invasive or based on drugs is significantly high”, says Anders Weilandt, CEO of Chordate.


Anders Weiland, CEO Chordate Medical, demonstrates the K.O.S technology to a group of Portuguese doctors.

INS 2022 this year gathers around 950 participants from 52 countries and has 32 exhibitors. The scientific program is aimed at clinics and researchers in neuromodulation with a focus on the latest technical developments and new treatment methods.

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia®, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter